The China-based contract research, development and manufacturing organization, or CRDMO, has agreed to sell the plant to Merck (NYSE:MRK) for around $500M, according to Reuters. In late December ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives ...

Per the deal terms, Merck (NYSE:MRK) will receive exclusive rights to develop, manufacture, and commercialize HRS-5346 globally except in Greater China. In exchange, the Rahway, New Jersey-based ...

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives Merck ...